TMCnet News
Wolters Kluwer Health Unveils Sentri7 Enhancements for Improved Antimicrobial StewardshipWolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today the release of updates to its Sentri7® electronic surveillance solution to improve the efficient and effective management of antimicrobials in hospitals and health systems. The advanced offering will help antimicrobial stewardship teams improve patient care and lower costs by optimizing use of drugs associated with antibiotic-resistant strains. Antimicrobial stewardship (AMS) has become a focal point of national initiatives to combat escalating rates of infection from organisms that are resistant to many of the industry's most potent antibiotics. These organisms contribute to healthcare-associated infections (HAIs), which are responsible for significant morbidity and mortality as well as notable increases in the costs of care. AMS initiatives help combat the epidemic rate of antimicrobial misuse across the industry-widely reported at greater than 50%-by fostering optimal selection, dose and duration of antimicrobial therapies. "The rise in resistant infections is reaching a tipping point across the industry, requiring a strategic response from healthcare organizations, many which lack resources and adequate infection control measures to respond effectively," said Leo Barbaro, Vice President & General Manager, Clinical Terminologies and Surveillance, Wolters Kluwer Health, Clinical Solutions. "The enhanced functionality now available within Sentri7 will equip healthcare organizations with the tools needed to implement effective programs that drive appropriate use of antimicrobials and proactive intervention." Combining real-time AMS functionality, clinical content and consulting services, Sentri7 provides key components to help healthcare facilities optimize antimicrobial stewardship programs (ASPs). Through a real-time, continuously generated antibiogram and an on-demand days-of-therapy (DOT) report, Sentri7 alerts clinicians to the improper use of antimicrobials and guides them to take proper actions while also providing a means of measuring stewardship program performance. Wolters Kluwer Clinical Decision Support Guidance™ offers real-time clinical guidance for intervention opportunities and expert-driven suggestions for next steps, while Smart Alerts™ provides immediate and accurate feedback on optimal antimicrobial use. Rounding out the solution is ClinicalOneSource.com, a web-based resource center that provides in-depth insight into infection-related topics, and change management consulting services provided by a team of MAD-ID certified clinicians for efficient implementation of a successful ASP. Sentri7 is a web-based, real-time, decision support application that drives continuous improvement and empowers healthcare organizations to achieve excellence in care delivery. It supports multiple infection prevention responsibilities, including investigation of HAIs, isolation management, multi-drug resistant organism (MDRO) management and compliance with federal and state reporting requirements.
About Wolters Kluwer Health Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). Follow our official Twitter (News - Alert) handle: @WKHealth.
|
